Targeting the HER-kinase axis in cancer

被引：58

作者：

Gross, ME ^{[1
]}

Shazer, RL ^{[1
]}

Agus, DB ^{[1
]}

机构：

[1] Cedars Sinai Med Ctr, Louis Warschaw Prostate canc ctr, Los Angeles, CA 90048 USA

来源：

SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 01期

关键词：

D O I：

10.1053/j.seminoncol.2004.01.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases controls critical pathways involved in the differentiation, growth, division, and motility of normal epithelial cells. Most human solid tumors are of epithelial origin. The process of malignant transformation and progression in many cancers may depend on activation of ligands and receptors that function as part of the HER-kinase pathway. This signaling axis has earned increased attention because of the development of antibodies and small-molecule tyrosine kinase inhibitors that specifically target components of the HER-kinase axis for cancer therapy. This review focuses on the basic biology underlying HER-kinase pathway activation and the current state of development for agents that target this axis. In particular, the importance of pan-HER inhibitors is discussed. © 2004 Elsevier Inc. All rights reserved.

引用

页码：9 / 20

页数：12

共 108 条

[1]

Agus D, 2003, P AN M AM SOC CLIN, V22, P192

[2] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].

Agus, DB ;

Akita, RW ;

Fox, WD ;

Lewis, GD ;

Higgins, B ;

Pisacane, PI ;

Lofgren, JA ;

Tindell, C ;

Evans, DP ;

Maiese, K ;

Scher, HI ;

Sliwkowski, MX .

CANCER CELL, 2002, 2 (02) :127-137

[3] A potential role for activated HER-2 in prostate cancer [J].

Agus, DB ;

Akita, RW ;

Fox, WD ;

Lofgren, JA ;

Higgins, B ;

Maiese, K ;

Scher, HI ;

Sliwkowski, MX .

SEMINARS IN ONCOLOGY, 2000, 27 (06) :76-83

[4]

AKIYAMA T, 1987, J BIOL CHEM, V262, P5592

[5] Development of inhibitors for protein tyrosine kinases [J].

Al-Obeidi, FA ;

Lam, KS .

ONCOGENE, 2000, 19 (49) :5690-5701

[6]

Albanell J, 2003, ADV EXP MED BIOL, V532, P253

[7] Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells [J].

Alper, Ö ;

Bergmann-Leitner, ES ;

Bennett, TA ;

Hacker, NF ;

Stromberg, K ;

Stetler-Stevenson, WG .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (18) :1375-1384

[8]

BANERJI U, 2003, P AN M AM SOC CLIN, V22, P199

[9] Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin [J].

Baselga, J ;

Pfister, D ;

Cooper, MR ;

Cohen, R ;

Burtness, B ;

Bos, M ;

D'Andrea, G ;

Seidman, A ;

Norton, L ;

Gunnett, K ;

Falcey, J ;

Anderson, V ;

Waksal, H ;

Mendelsohn, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (04) :904-914

[10] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

← 1 2 3 4 5 6 7 8 9 10 →